Dr. G. Bozet, MD, Author At PanNASH

NASH Observatory Commented Articles Pathophysiology Articles

Natural History of NAFLD

GIn their paper, Raluca Pais and Thomas Maurel (Hôpital Pitié Salpetrière, Paris, France) propose a critical analysis of factors that are involved in the progression of the liver damage and the occurrence of extra-hepatic complications in patients with NAFLD. They also briefly discuss the impact of the heterogeneity of the clinical...

June 9, 2021

NASH Observatory Commented Articles

Sequential combination of NIS-4, MACK-3, and FAST scores

For Y. J. Zhou, et al., there is an urgent need to identify patients who are at risk of developing NASH. Traditional, non-invasive tests have been developed to identify either NASH or advanced fibrosis. However, these tests do not accurately detect patients who are at risk of NASH.
Harrison et al. developed and validated the NIS4 test that provides...

June 7, 2021

NASH Observatory Commented Articles Definitions Articles

Lean NAFLD: a distinct entity

A significant subset of patients with NAFLD are lean, but the underlying pathophysiology in this group is poorly understood. F. Chen et al. (Westmead Hospital, University of Sydney, Australia) investigated the pathogenesis of lean NAFLD in a cohort of Caucasian patients with biopsy proven disease, and in experimental murine models...

June 7, 2021

NASH Observatory Commented Articles Epidemiology Articles

Epidemiology: NAFLD from 1999 to 2018 in China

For J. Zhou et al. (Wuhan University, China), NAFLD has become the most prevalent liver disorder in China but has not received sufficient attention. NAFLD-related advanced liver disease and its mortality along with its overall disease burden are expected to increase substantially. In their meta-analysis, the authors summarise eight...

June 2, 2021

NASH Observatory Commented Articles Ppar Articles

PPARs as candidates for the treatment of NAFLD

The prevalence of NAFLD is dramatically increasing in developed countries, but no approved therapy is available. Most of the current pharmacological strategies target comorbidities, such as manifestations of metabolic syndrome. In addition, none of used medications improve fibrosis, which is the strongest indicator of mortality in NAFLD...

May 31, 2021

NASH Observatory Commented Articles

OSA with NAFLD in patients with obesity: an observational study

A growing amount of evidence has correlated obstructive sleep apnea (OSA) with the presence of NAFLD and it has been demonstrated a direct association between the severity of the former and the progression of the latter. Thus, OSA patients should be screened for the presence and severity of NAFLD...

May 27, 2021

Management Articles Commented Articles NASH Observatory Ppar Articles

Fibrosis in NASH: targeted therapies

Progress in uncovering pathogenic determinants of fibrosis in NASH include metabolic dysregulation in hepatocytes that induce inflammation and cytokine secretion leading to cell injury and apoptosis, among others.This review by T. M. Huisman et al. (Division of Liver Diseases, Icahn School of Medicine at Mount Sinai...

May 25, 2021

NASH Observatory Commented Articles

Patients with psoriasis: a screening algorithm for NAFLD

Psoriasis is an immune-mediated systemic inflammatory disease that may be associated with arthritis, cardiovascular diseases, metabolic syndrome including diabetes and obesity and as identified more recently, NAFLD, that occurs in approximately 50 % of all patients with psoriasis. In 2019, the American Academy of Dermatology...

May 20, 2021

NASH Observatory Commented Articles Epidemiology Articles

Adult US population: NAFLD prevalence 38%, NASH 14%

S. A. Harrison et al. (Radcliffe Department of Medicine, University of Oxford, UK) prospectively assessed the prevalence and severity of NAFLD/NASH in a cohort of asymptomatic middle-aged Americans attending a colonoscopy class at a gastroenterology clinic. Screening for NAFLD was performed using magnetic resonance...

May 17, 2021

Management Articles Commented Articles NASH Observatory Ppar Articles

Management of NAFLD: a review

As explained in the review by M. L. Petroni et al. (“Alma Mater” University, Bologna, Italy), several drugs are under investigation according to the agreed targets of reduced NASH activity without worsening of fibrosis or improving fibrosis without worsening of NASH.
Anti-inflammatory, anti-fibrotic agents and metabolism modulators...

May 10, 2021

Management Articles Commented Articles NASH Observatory

Comparative analysis of different guidelines

In their review, Y. Ando and J. H. Jou (Oregon Health & Science University Hospital, Portland, Oregon, USA) summaries updated guideline and guidance recommendations for the management of adult NAFLD. They highlight key difference between US, Asian, and European recommendations; and provide key updates...

May 5, 2021

NASH Observatory Commented Articles Epidemiology Articles

Changing trends of liver transplantation and mortality from NAFLD

This review by A. Majumdar (Australian National Liver Transplant Unit, Royal Prince Alfred Hospital, Sydney, and University of Sydney, Australia) and E. Tsochatzis (UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, London, and Sheila Sherlock Liver Centre, Royal Free Hospital, London, UK) outlines the current epidemiology, natural history...

May 3, 2021